Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Abiraterone and ADT in High-Risk Prostate Cancer
NCT04356430Phase 2Unknown
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2019
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Abiraterone Acetate Tablets (I) in prostate cancer (PCa), sponsored by Nanjing Drum-Tower Hospital. Status: unknown.
02
Drugs
Abiraterone Acetate Tablets (I)
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04356430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04356430.